Dr. Evans on Challenges of Immunotherapy in Lung Cancer

Tracey Evans, MD
Published: Friday, Mar 24, 2017



Tracey L. Evans, MD, associate professor of Clinical Medicine at Penn Medicine, discusses the challenges associated with immunotherapy for the treatment of patients with lung cancer.

Although immunotherapy is showing promise in lung cancer, it is not for every patient. Dealing with the disappointment from both the patients and their families can be very difficult, says Evans.

Also, pseudo-progression is sometimes seen in the first-line setting with immune-based agents in this disease, adds Evans. If this seems to be occurring, switching to chemotherapy may be a viable option.
 


Tracey L. Evans, MD, associate professor of Clinical Medicine at Penn Medicine, discusses the challenges associated with immunotherapy for the treatment of patients with lung cancer.

Although immunotherapy is showing promise in lung cancer, it is not for every patient. Dealing with the disappointment from both the patients and their families can be very difficult, says Evans.

Also, pseudo-progression is sometimes seen in the first-line setting with immune-based agents in this disease, adds Evans. If this seems to be occurring, switching to chemotherapy may be a viable option.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Publication Bottom Border
Border Publication
x